Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Goss, Paul
Item TypeName
Academic Article Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Academic Article Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Academic Article Extending the benefits of adjuvant therapy in early HR+ breast cancer.
Academic Article Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches.
Academic Article Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Academic Article Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Academic Article Standardization of Estrogen and Progesterone Receptor Assay Values
Academic Article Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Academic Article Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.
Academic Article NCIC CTG MA17: Updated analysis on disease-free survival (DFS) according to estrogen receptor and progesterone receptor status of the primary tumor
Academic Article Standardization of estrogen and progesterone receptor assay values (Abstract #5101)
Academic Article Expression of the proliferation antigen Ki-67 and estrogen (ER) and progesterone (PR) receptors in paraffin-embedded cell blocks correlate with corresponding histologic sections of breast carcinoma
Academic Article Efficacy of Letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: NCIC CTG MA.17
Academic Article Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Academic Article NCIC CTG MA17: disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor (Abstract #2042)
Academic Article NCIC CTG MA.17: Disease-free survival according to estrogen receptor and progesterone receptor status of the primary tumor
Concept Progesterone
Concept Receptors, Progesterone
Academic Article Competing risks in low-risk breast cancer.
Academic Article Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
Academic Article Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Academic Article Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Academic Article Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.
Academic Article Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy.
Academic Article Extending endocrine therapy in women with hormone receptor-positive breast cancer.
Academic Article Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Academic Article A randomized, double-blind phase II trial of exemestane with or without MM-121 in postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+), HER2-negative breast cancer.
Search Criteria
  • Progesterone
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.